Pharmacokinetics of baricitinib in critically ill COVID-19 patients

BACKGROUND: The use of the selective Janus Kinase 1/2 inhibitor baricitinib has shown a survival benefit in mechanically ventilated COVID-19 patients but this is not without adverse drug reactions. Although critically ill patients are at risk of altered drug exposure, data on baricitinib pharmacokin...

Descripción completa

Detalles Bibliográficos
Autores principales: Massart, Nicolas, Fillatre, Pierre, Lemaitre, Florian, Mari, Arnaud, Tron, Camille
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. on behalf of The Canadian Society of Clinical Chemists. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284613/
https://www.ncbi.nlm.nih.gov/pubmed/37353137
http://dx.doi.org/10.1016/j.clinbiochem.2023.110601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284613/
https://www.ncbi.nlm.nih.gov/pubmed/37353137
http://dx.doi.org/10.1016/j.clinbiochem.2023.110601

Ejemplares similares